Dec. 5 at 7:01 PM
$IBO $DSS For anyone tracking Impact Biomedical’s past collaborations: I’ve completed a full rebuild of my scientific portfolio, including upgraded versions of technologies previously associated with them—Equivir, Linebacker, antivirals, repellents, and more. These systems are new, materially different, and outside the scope of prior patents. I have also issued formal notices regarding certain earlier IP arrangements. My updated portfolio will be detailed in upcoming scientific and media releases, giving the public clear visibility. This is a factual update, not investment advice.